Nanostructured Ultrafiltration Membranes for Biological Applications

用于生物应用的纳米结构超滤膜

• 批准号: 7611645
• 负责人: Oleg G. Polyakov
• 金额: $ 10万
• 依托单位: SYNKERA TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-05-15 至 2009-11-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7611645
• 关键词: Address; Aluminum Oxide; Arts; Biochemical; Biological; Biological Factors; Biological Products; Biomedical Research; Blood; Caliber; Cardiac Surgery procedures; Caring; Ceramics; Development; Drops; Economics; End stage renal failure; Ensure; Evaluation; Family; Government; Hemodialysis; Industry; Institution; Laboratory Study; Letters; Measures; Medical; Medical Research; Membrane; Methods; Mission; Molecular Weight; National Institute of General Medical Sciences; Nucleic Acids; Performance; Persons; Phase; Polysaccharides; Process; Production; Property; Proteins; Research; Research Project Grants; Sampling; Secure; Small Business Innovation Research Grant; Technology; Testing; Time; Ultrafiltration; Water; analog; base; commercialization; cost; glucose sensor; improved; indexing; innovation; interest; macromolecule; nanoscale; nanostructured; novel; product development; public health relevance; sensor

DESCRIPTION (provided by applicant): Ultrafiltration membranes are being used widely by bio- and health-related research institutions as well as by biopharmaceutical industry for rapid size-based purification and separation of macromolecules, including proteins, nucleic acids and polysaccharides. Important medical applications include hemodialysis (treatment of end-stage renal failure) and open-heart surgery (blood oxygenation). In spite of the fact that a wide range of membranes with different specifications is available commercially, there is a strong need for improvement of membranes selectivity. The main approach to that is to narrow down pore size distribution, which is a challenge for the existing types of ultrafiltration membranes. This multi-phase Small Business Innovation Research project aims to develop and commercialize novel ultrafiltration membranes with unprecedented sharp and controllable molecular-weight cut-off and reduced fouling. Such membranes are needed to fully realize the potential benefits of ultrafiltration in the processing of macromolecules of biological and medical interest. The targeted product - novel membranes - will be suitable as drop-in replacements of the state-of-the- art membranes in commercial membrane holders. The proposed development will drastically improve rapid purification and separation of natural products in biochemical and medical research and in medical care applications and thus is directly relevant to the mission of the National Institute Of General Medical Sciences. The main Phase I objective is to demonstrate feasibility of the proposed approach by fabricating and testing ultrafiltration membranes and confirming their enhanced performance versus commercial analogs. To ensure successful Phase II product development and Phase III commercialization, an early partnership has been secured with a developer of low-cost non-invasive glucose sensors. PUBLIC HEALTH RELEVANCE: The project addresses a significant problem in biomedical research and medical care: rapid size-based purification and separation of macromolecules, including proteins, nucleic acids and polysaccharides. The development of novel advanced ultrafiltration membranes with unprecedented sharp and controllable molecular-weight cut-off and reduced fouling is proposed. The proposed technology will enable a novel family of high-performance membranes for use in biochemical analysis, laboratory studies, and, potentially, in hemodialysis for treatment of end-stage renal failure and in open heart surgery for blood oxygenation.

描述（由申请人提供）：超滤膜被生物和健康相关的研究机构以及生物制药行业广泛使用，用于快速基于大小的纯化和大分子的分离，包括蛋白质，核酸，核酸和多糖。重要的医学应用包括血液透析（治疗终末期肾衰竭）和心脏直视手术（血液氧化）。尽管在商业上可以使用各种规格不同的膜，但仍需提高膜选择性。这样做的主要方法是缩小孔径分布，这是现有类型的超滤膜的挑战。这个多相的小型企业创新研究项目旨在开发和商业化新颖的超滤膜，并以前所未有的尖锐和可控的分子量截止和减少结垢。需要这样的膜以充分实现超滤在生物和医疗利益的大分子中的潜在益处。靶向产品 - 新型膜 - 将作为商用膜持有人中最先进的膜的倒入替代品。拟议的开发将大大改善生物化学和医学研究以及医疗应用中天然产物的快速净化和分离，因此与国家一般医学科学研究所的任务直接相关。 I阶段的主要目标是通过制造和测试超滤膜并确认其增强的性能与商业类似物来证明所提出的方法的可行性。为了确保成功的II期产品开发和III期商业化，已经与低成本非侵入性葡萄糖传感器的开发商确保了早期的伙伴关系。公共卫生相关性：该项目解决了生物医学研究和医疗护理中的一个重大问题：基于大小的纯化和大分子的分离，包括蛋白质，核酸和多糖。提出了新型高级超滤膜的发展，并提出了前所未有的尖锐和可控的分子量截止和减少的结垢。提出的技术将使一个新型的高性能膜家族用于生化分析，实验室研究，并有可能在血液透析中用于治疗终末期肾衰竭和开放性心脏手术的血液氧合。